IMS's Incivek reporting hitch spurs stock swing

IMS Health continues to assess a data-supply glitch that led to an underreporting of ­prescriptions for Vertex Pharmaceuticals' hepatitis C drug Incivek.

During the period in question—the last two weeks of September—IMS data showed relatively flat TRx of the drug. Various financial analysts interpreted the dip as a sign that usage of the new drug had peaked.

Instead, IMS said, a key supplier had missed some mail order prescriptions. IMS adjusted for the issue but due to the short duration is not restating the history, a spokseman for the company said.

But when the company initially disclosed the hitch, Vertex shares jumped 7% as investors expected that a new sales report would reflect more comprehensive estimates. Then, when new IMS data still did not show sales had risen, shares declined by more than 6%.

As of early October, Incivek scripts continued to climb. Vertex is battling Merck's Victrelis for hep-C market share.

Because of IMS's script-reporting issues, rival Rx tracker Wolters Kluwer said it verified the quality of data it received from vendors for Incivek and Victrelis, saying it had not experienced a significant loss of data and continued to receive “a consistent data flow.”

A Vertex spokesperson said the firm doesn't comment on IMS data.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.